Login / Signup
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
Send us Feedback
Amgen (AMGN)
SUMMARY
BULLS
BEARS
DATA CENTRAL
STOCK CHART
OPERATING METRICS
REVENUE SOURCES
BALANCE SHEET
INCOME STMT
CASH FLOW
Key Metrics for AMGN as compared to
Top Competitors
Biotechnology
Drug Manufacturers - Major
Pharma & Healthcare
All values TTM unless otherwise noted (*)
INDUSTRY METRICS (
See all
)
Revenue
►
14.6B
HIGH
R&D Expense
►
3.03B
AVG
R&D/Sales Ratio
►
20.2%
HIGH
Number of Drugs in Phase I
►
13.0
AVG
Number of Drugs in Phase II
►
14.0
LOW
Number of Drugs in Phase III
►
10.0
AVG
Gross Margin
►
84.7%
Number of Drugs in Phase I
Number of Drugs in Phase II
Number of Drugs in Phase III
R&D/Sales Ratio
Research and Development Expense
Revenue
Net Income
Operating Income
INCOME STATEMENT (
See all
)
Revenue
►
14.6B
HIGH
EBITDA
►
6.78B
AVG
Net Income
►
4.41B
HIGH
Revenue Growth
►
-0.6%
AVG
Net Income Growth
►
41.6%
AVG
Operating Margin
►
39.8%
HIGH
Net Margin
►
30.1%
HIGH
Revenue, Net Income, and Net Margin
Revenue, Gross Profit, and Gross Margin
Operating Income
Ebit
Income Before Taxes
Net Income from Continuing Ops
Interest vs Continuing Income
Interest Coverage
Operating Expenses
Research & Development
SG&A
Amortization & Depreciation
BALANCE SHEET (most recent quarter) (
See all
)
Debt / Equity
►
0.818
AVG
Current Ratio
►
3.89
AVG
Quick Ratio
►
3.44
AVG
Interest Coverage Ratio
►
11.9
AVG
Book Value Per Share
►
5.17
Cash Per Share
►
0.718
Loading...
STOCK SUMMARY
Open
54.71
Day Range
53.87
-
54.94
52 Week Range
44.96
-
64.76
Volume
6.33M
Avg Volume (3 mo)
7.08M
Shares Outstanding
1.01B
Market Cap
55.5B
VALUATION
Price to Earnings (P/E)
►
0
Price to Book (P/B)
►
0
Price to Sales (P/S)
►
0
Return on Assets (ROA)
►
13%
AVG
Return on Equity (ROE)
►
22.1%
AVG
EV/EBITDA
►
1.98
VERY LOW
Dividend Yield
0%
AVG
ANALYST RECOMMENDATIONS
OWNERSHIP
Net Insider Buying 3mo
0%
Net Insider Buying 6mo
-4.7%
Net Insider Buying 1yr
-14.1%
Held by insiders
0.3%
Held by institutions
63.1%